Jörg Trojan

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Locally Advanced

Vascular Endothelial Growth Factor

Top Venues

Journal of hepatocellular carcinoma

Liver international : official journal of the International Association for the Study of the Liver

This page only lists publications with an associated author ORCID identifier.

Publications

Vera Himmelsbach, Christine Koch, Jörg Trojan, Fabian Finkelmeier
Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? Journal of hepatocellular carcinoma 11 (2024)
Vera Himmelsbach, Christine Koch, Jörg Trojan, Fabian Finkelmeier
Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions? Journal of hepatocellular carcinoma 11 (2024)
Maximilian N Kinzler, Jan Jeroch, Christina Klasen, Vera Himmelsbach, Christine Koch, Fabian Finkelmeier, Jörg Trojan, Stefan Zeuzem, Ursula Pession, Henning Reis, Melanie C Demes, Peter J Wild, Dirk Walter
Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. Journal of cancer research and clinical oncology (2023)
Jörg Trojan, Albrecht Hoffmeister, Bruno Neu, Stefan Kasper, Alexander Dechêne, Christian Jürgensen, Jörg Schirra, Ralf Jakobs, Dan Palmer, Pål Kristian Selbo, Hans Olivecrona, Lena Finnesand, Anders Høgset, Per Walday, Richard Sturgess
Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma. The oncologist 27 (6) (2022)
Maximilian N Kinzler, Angelika Stehle, Falko Schulze, Michael Hogardt, Thomas A Wichelhaus, Volkhard A J Kempf, Fabian Finkelmeier, Jörg Trojan, Stefan Zeuzem, Andreas A Schnitzbauer, Wolf O Bechstein, Peter J Wild, Dirk Walter
Colonization with multidrug-resistant organisms is associated with impaired survival of patients with surgically resected cholangiocarcinoma. Liver international : official journal of the International Association for the Study of the Liver (2022)
Jörg Trojan
Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 80 (12) (2021)
Jörg Trojan, Patrick Mollon, Bruno Daniele, Florence Marteau, Lidia Martín, Yuxin Li, Qing Xu, Piscaglia Fabio, Renata Zaucha, Debashis Sarker, Ho Yeong Lim, Marino Venerito
Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Advances in therapy 38 (5) (2021)
Jörg Trojan, Sebastian Stintzing, Oliver Haase, Christine Koch, Paul Ziegler, Melanie Demes, Ivan Jelas
Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer. The oncologist 26 (12) (2021)
Maria Rita Gaiser, Sylvie Lorenzen, Kirsten Merx, Jörg Trojan, Janja Ocvirk, Thomas J Ettrich, Salah-Eddin Al-Batran, Holger Schulz, Nils Homann, Hans-Peter Feustel, Michael Schatz, Melanie Kripp, Nadine Schulte, Steffen Heeger, Soetkin Vlassak, Winfried Koch, Ralf-Dieter Hofheinz
Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score. Cancer medicine 8 (9) (2019)